Does somatostatin-14 have an impact on gastric fistula after laparoscopic sleeve gastrectomy?
The main complications following laparoscopic sleeve gastrectomy (LSG) is gastric fistula (GF). Gastric fistula is a rare but serious complication (affecting 2 % of LSGs). Somatostatin-14 and its analogs are mainly used in the prevention and curative treatment of digestive fistulas. These compounds inhibit secretions in the pancreas, stomach, and small intestine. Treatment with somatostatin-14 increases the spontaneous closure rate and reduces the closure time of postoperative digestive fistulas. However, the impact of somatostatin-14 on GF after LSG has not been studied. We report on a prospective, non-randomized, single-center, case-matched study of patients receiving somatostatin-14 after a post-LSG GF was discovered. Our results suggest that use of somatostatin-14 is associated with a shorter length of hospital stay and (perhaps) a shorter treatment period.
Department of Digestive Surgery, Amiens University Medical Center and the Jules Verne University of Picardie, Amiens, France.
Lionel
L
Rebibo
Flavien
F
Prevot
Abdennaceur
A
Dhahri
Jean-Marc
JM
Regimbeau
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects* / Q000379:methods; D005747:Gastric Fistula / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D010535:Laparoscopy / Q000009:adverse effects / Q000379:methods; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D012189:Retrospective Studies; D013004:Somatostatin / Q000627:therapeutic use*; D055815:Young Adult
D013004:Somatostatin